Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
APMIS ; 129(11): 631-640, 2021 Nov.
Article in English | MEDLINE | ID: mdl-34561922

ABSTRACT

Burkholderia cenocepacia complex is associated with high transmissibility, virulence, and poor prognosis in cystic fibrosis (CF) patients. However, extrapulmonary infections are rare. We investigated the genome of a B. cenocepacia IIIA isolated from a liver abscess in a Brazilian CF patient and compared it to strain J2315. The whole genome was sequenced, and contigs were annotated by Rapid Annotation using Subsystem Technology. The Pathosystems Resource Integration Center was used to map antimicrobial and virulence genes. The genomic island (GIs) analysis was performed using two prediction methods, and the presence of putative plasmids and insertion sequences (ISs) was investigated. The isolate was confirmed as B. cenocepacia IIIA to ST-28 (ET12 lineage). A total of 64 genes for antimicrobial resistance and 47 genes related to virulence were identified. Among the virulence factors, there was a predominance of factors related to the invasion mechanism, to the flagellar biosynthesis protein, and to the RNA polymerase sigma factor for flagellar operon (cdpA). Two IS families (IS3 and IS5) and only one plasmid were found. On average 56 GIs were predicted by at least one of the methods applied. Comparative analysis showed resistance mechanisms and virulence factors revealing invasive determinants used by B. cenocepacia IIIA (ET12) in the process of disease spread to other infection sites (extrapulmonary) of highly virulent strains in CF patients.


Subject(s)
Burkholderia Infections/microbiology , Burkholderia cenocepacia/genetics , Cystic Fibrosis/microbiology , Genome, Bacterial/genetics , Liver Abscess/microbiology , Adolescent , Brazil , Burkholderia Infections/complications , Burkholderia cenocepacia/classification , Burkholderia cenocepacia/isolation & purification , Cystic Fibrosis/complications , DNA Transposable Elements/genetics , DNA, Bacterial/genetics , Drug Resistance, Bacterial/genetics , Female , Genes, Bacterial/genetics , Genomic Islands/genetics , Humans , Liver Abscess/complications , Plasmids/genetics , Virulence Factors/genetics
2.
J Glob Antimicrob Resist ; 17: 195-197, 2019 06.
Article in English | MEDLINE | ID: mdl-31005734

ABSTRACT

OBJECTIVES: The aim of this study was to report the draft genome sequence of the bacteriocinogenic strain Enterococcus faecium E86. Bacteriocins are prokaryotic peptides or proteins with antimicrobial activity. The genome information may contribute to the identification of enterocins produced by this strain that exhibit inhibitory activity against the foodborne pathogen Listeria monocytogenes and vancomycin-resistant enterococci (VRE) involved in human infections, among other bacterial genera and species. METHODS: An Illumina MiSeq platform was used for genome sequencing. De novo assembly of 5 735 838 paired-end reads was done using the A5-miseq pipeline, yielding >300-fold average genome coverage. Genome annotation was performed by the RAST server, and mining of the bacteriocinogenic gene clusters was done using the BAGEL3 and antiSMASH v.4 platforms. RESULTS: The total scaffold size was determined to be 2 689 107 bp, approximately 2.7 Mbp, featuring a G + C content of 38.1%. The genome contains 2858 coding sequences and 74 RNA genes. Genome analyses revealed the presence of: 30 genes involved in drug resistance; 2 bacteriocinogenic gene clusters (for enterocin P and enterocin TW21); EntiTW21, a novel bacteriocin immunity protein and a novel multilocus sequence type (ST1500). CONCLUSION: This work highlights the potential biotechnological application of this strain for the production of enterocin P, a bacteriocin that can be employed in the food industry as a biopreservative against L. monocytogenes and as an alternative to classical antibiotics against VRE.


Subject(s)
Antimicrobial Cationic Peptides/biosynthesis , Bacteriocins/biosynthesis , Enterococcus faecium/genetics , Genome, Bacterial , Anti-Bacterial Agents/pharmacology , Antimicrobial Cationic Peptides/genetics , Antimicrobial Cationic Peptides/pharmacology , Bacteriocins/genetics , Bacteriocins/pharmacology , Drug Resistance, Bacterial/genetics , Humans , Listeria monocytogenes/drug effects , Microbial Sensitivity Tests , Multigene Family , Sequence Analysis, DNA , Vancomycin-Resistant Enterococci/drug effects , Whole Genome Sequencing
3.
Microbiol Res ; 198: 36-46, 2017 May.
Article in English | MEDLINE | ID: mdl-28285660

ABSTRACT

Hyicin 3682, the first bacteriocin reported for Staphylococcus hyicus, is a BsaCOL variant produced by S. hyicus 3682, a strain isolated from bovine milk. Hyicin 3682 is found in the culture supernatant, is bactericidal and its producing strain exhibits a much broader spectrum of antimicrobial activity than the producing strain of BsaCOL against several Gram-positive bacteria, which include foodborne pathogens, food-spoilage microorganisms and bacterial species of medical and veterinary importance. Sequencing of the genome of S. hyicus 3682 provided the nucleotide sequence of the entire gene cluster involved in hyicin 3682 production, which seems to be located on pRJ109, the single plasmid carried by this strain. This gene cluster is expressed and consists of 8525bp and of eight genes (hyiA, hyiB, hyiC, hyiD, hyiP, hyiF, hyiE and hyiG) encoded on the same DNA strand. The mature lantibiotic exhibits 91% identity to BsaCOL and its molecular mass was found to be ∼26Da higher due to two amino acid substitutions. S. hyicus 3682 proved to be only partially immune to its cognate bacteriocin up to 1024 AU/ml. Therefore, hyicin 3682, the first Bsa variant reported in coagulase-negative staphylococci, does exhibit antimicrobial and siblicidal activities.


Subject(s)
Anti-Bacterial Agents/metabolism , Bacteriocins/genetics , Bacteriocins/metabolism , Staphylococcus hyicus/genetics , Staphylococcus hyicus/metabolism , Amino Acid Sequence , Animals , Anti-Bacterial Agents/chemistry , Bacteriocins/chemistry , Biosynthetic Pathways/genetics , Cattle , Gene Order , Genes, Bacterial , Genome, Bacterial , Gram-Positive Bacteria/drug effects , Microbial Sensitivity Tests , Milk/microbiology , Molecular Sequence Data , Molecular Weight , Multigene Family , Sequence Analysis, DNA , Staphylococcus hyicus/isolation & purification
4.
Exp Mol Pathol ; 101(1): 66-73, 2016 08.
Article in English | MEDLINE | ID: mdl-27260309

ABSTRACT

Esophageal squamous cell carcinoma (ESCC) is the most frequent esophageal tumor in the world. ESCC presents late diagnosis, highly aggressive behavior and poor survival. Changes in tumor cell energy metabolism appear to have a prominent role in malignant transformation. Tumor cells consume glucose avidly and produce lactic acid, even under normoxia. Among the factors that may contribute to the stimulation of glycolysis in tumor cells, there are changes in the glycolytic pathway enzymes such as: pyruvate kinase M1 and M2 (PKM2 and PKM1), hexokinase II (HKII), glucose transporter isoform 1 (GLUT-1), and transcription factor induced by hypoxia (HIF1α), responsible for the transcription of proteins cited. The objective of this study is to evaluate the alterations of these proteins and their association with clinicopathological data in ESCC. We performed immunohistochemistry to determine HIF-1α, GLUT-1, PKM1, PKM2, HK2 and Ki67-expression in ESCC patients and controls. Also, we used RT-qPCR to evaluated mRNA expression of GLUT-1 in esophageal mucosa of individuals without cancer, but are alcohol drinkers and tobacco smokers. Our results showed the exclusively expression of GLUT-1 in tumors cells and dysplastic samples. We also observed a compartmentalization of the expression of PKM1 and PKM2 in relation to tumor cells and stroma associated to tumor areas. All of the proteins evaluated, excepted GLUT-1, were frequently detected in normal mucosa. No correlations between clinicopathological features and protein expressions were observed. GLUT-1 expression appears in initial tumor lesions and is maintained through ESCC evolution. We reported for the first time PKM1 staining in normal esophagus and ESCC, being mostly present in more differentiated cells.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Esophageal Neoplasms/metabolism , Glucose/metabolism , Glycolysis , Adolescent , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/enzymology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Epithelium/enzymology , Epithelium/pathology , Esophageal Neoplasms/enzymology , Esophageal Neoplasms/genetics , Esophageal Neoplasms/pathology , Esophageal Squamous Cell Carcinoma , Female , Gene Expression Regulation, Neoplastic , Glucose Transporter Type 1/genetics , Glucose Transporter Type 1/metabolism , Hexokinase/metabolism , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Immunohistochemistry , Ki-67 Antigen/metabolism , Male , Middle Aged , Mucous Membrane/enzymology , Mucous Membrane/pathology , Pyruvate Kinase/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Risk Factors , Tumor Microenvironment , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...